Volume 70, Issue 9 e30470
RESEARCH ARTICLE

Neoadjuvant chemotherapy or upfront surgery in hepatoblastoma: A multicenter retrospective study

Yu Tian

Yu Tian

Department of Pediatric Surgery, Capital Institute of Pediatrics-Peking University Teaching Hospital, Beijing, China

Research Unit of Minimally Invasive Pediatric Surgery on Diagnosis and Treatment, Chinese Academy of Medical Sciences 2021RU015, Beijing, China

Search for more papers by this author
Xinghai Chen

Xinghai Chen

Department of Pediatric Surgery, Capital Institute of Pediatrics-Peking University Teaching Hospital, Beijing, China

Search for more papers by this author
Fan Yu

Fan Yu

School of Public Health, China Medical University, Shenyang, China

Search for more papers by this author
Jiayi Feng

Jiayi Feng

Department of Pediatric Surgery, Capital Institute of Pediatrics-Peking University Teaching Hospital, Beijing, China

Search for more papers by this author
Guimin Huang

Guimin Huang

Child Health Big Data Research Center, Capital Institute of Pediatrics, Beijing, China

Search for more papers by this author
Xianghai Ren

Xianghai Ren

Department of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China

Search for more papers by this author
Huimin Hu

Corresponding Author

Huimin Hu

Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China

Correspondence

Long Li, Head of Department of Pediatric Surgery, Capital Institute of Pediatrics, Beijing, 100020, China.

Email: [email protected]

Weiling Zhang and Huimin Hu, Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.

Email: [email protected] and [email protected]

Search for more papers by this author
Weiling Zhang

Corresponding Author

Weiling Zhang

Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China

Correspondence

Long Li, Head of Department of Pediatric Surgery, Capital Institute of Pediatrics, Beijing, 100020, China.

Email: [email protected]

Weiling Zhang and Huimin Hu, Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.

Email: [email protected] and [email protected]

Search for more papers by this author
Long Li

Corresponding Author

Long Li

Department of Pediatric Surgery, Beijing Tsinghua Changgeng Hospital, Beijing, China

Correspondence

Long Li, Head of Department of Pediatric Surgery, Capital Institute of Pediatrics, Beijing, 100020, China.

Email: [email protected]

Weiling Zhang and Huimin Hu, Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.

Email: [email protected] and [email protected]

Search for more papers by this author
First published: 07 June 2023
Citations: 1

Abstract

Background

We retrospectively investigated the role of neoadjuvant chemotherapy in low-risk patients with hepatoblastoma (HB) who underwent curative resection between February 2009 and December 2017. We also verified the feasibility of the risk stratification system to select the optimal patients for upfront surgery.

Procedure

We compared 5-year overall survival (OS) and event-free survival (EFS) between the upfront surgery (n = 26) and neoadjuvant chemotherapy (n = 104) groups at three oncology centers in Beijing, China. To reduce the effect of covariate imbalance, propensity score matching (PSM) was used. We explored whether preoperative chemotherapy affected surgical outcomes and identified the risk factors for events and death, including resection margin status, PRETreatment EXTent of disease stages, age, sex, pathology classification, and α-fetoprotein levels.

Results

The median follow-up period was 64 (interquartile range 60–72) months. After PSM, 22 pairs of patients were identified, and the patient characteristics were similar for all variables included in PSM. In the upfront surgery group, the 5-year EFS and OS rates were 81.8% and 86.3%, respectively. In the neoadjuvant chemotherapy group, the 5-year EFS and OS rates were 81.8% and 90.9%, respectively. No significant differences in EFS or OS were observed between the groups. Pathological classification was the only risk factor for death, disease progression, tumor recurrence, other tumors found during HB diagnosis, and death from any cause (p = .007 and .032, respectively).

Conclusions

Upfront surgery achieved long-term disease control in low-risk patients with resectable HB, thus reduced the cumulative toxicity of platinum-based chemotherapy drugs.

CONFLICT OF INTEREST STATEMENT

The authors of this study have no affiliations or associations with any organization/entity with any financial or non-financial interest in the subject matter or materials discussed in this manuscript.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.